Navigation Links
Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases

CAMBRIDGE, Mass., June 2 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has promoted F. Stephen Laroux, Ph.D., to the new position of director, immunology and inflammatory diseases, effective immediately. Dr. Laroux joined the company as a scientist in 2007. Today, he leads the team of Cequent researchers developing drug candidates using Cequent's proprietary tkRNAi delivery platform against a series of targets thought to be important in gastro-intestinal diseases, such as inflammatory bowel disease (IBD). Dr. Laroux's current study portfolio includes the target associated with Cequent's partnership with Novartis, as well as Cequent's in-house IBD program.

"While we are furthest along with our drug candidate CEQ508, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis) -- our IBD program is actually the company's largest, and Stephen has been critical to our rapid progress over the past 18 months," said Cequent President and CEO, Peter Parker. "We started with fourteen potential therapeutic targets for IBD, including several in our partnership with Novartis. We have finished in vivo testing on candidate treatments against our first four targets, and all have exhibited significant efficacy. This is a testament to the promise of our tkRNAi technology -- but also to Stephen's skills and tenacity in both study design and execution. Thanks to his leadership and hard work we are now positioned to file two IND (investigational new drug) applications with the FDA for IBD therapeutics next year."

Dr. Laroux completed a post-doctoral fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School where he conducted research focused on innate immune responses to bacteria as well as the role of the immune system in chronic disease. Prior to his tenure at BIDMC, Dr. Laroux conducted research into the immunology of diseases such as IBD, rheumatoid arthritis, ischemia-reperfusion, and myocardial infarction, co-authoring more than 40 publications in peer-reviewed journals. Dr. Laroux received a Ph.D. in molecular and cellular physiology (Chancellor's Award) and a master's degree in human physiology, both from Louisiana State University.

About Cequent Pharmaceuticals, Inc. (

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory disease to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cequent Names Ted Hibben Chief Business Officer
2. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. AIAA names top ten emerging aerospace technologies of 2009
7. Microbia, Inc. Names Alex Chu as Vice President of Process Development
8. Premier Research Names Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance
9. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Hospira Names Brian Meadows Supply Chain Chief
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  AbbVie, is introducing Good ... on a daily routine for managing the life-long condition ... can affect the way the body absorbs it so ... a daily routine are important. The goal of the ... better manage their hypothyroidism by establishing a daily routine, ...
(Date:11/30/2015)... CA (PRWEB) , ... November ... ... Intelligence Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL ... organizations maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide ...
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
Breaking Biology Technology:
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):